<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04901676</url>
  </required_header>
  <id_info>
    <org_study_id>ARO_21_018_001</org_study_id>
    <nct_id>NCT04901676</nct_id>
  </id_info>
  <brief_title>Leronlimab in Moderately Ill Patients With COVID-19 Pneumonia</brief_title>
  <official_title>A Phase 3, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Efficacy and Safety of Leronlimab in Combination With Standard of Care for Moderately Ill Patients With Coronavirus Disease 2019 (COVID-19) Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Israelita Albert Einstein</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CytoDyn, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Israelita Albert Einstein</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C&#xD;
      chemokine receptor type 5 (CCR5). Disruption of the C-C chemokine ligand 5 (CCL5)-CCR5 axis&#xD;
      via leronlimab-mediated CCR5 blockade might prevent pulmonary trafficking of pro-inflammatory&#xD;
      leukocytes and dampen pathogenic immune activation in coronavirus disease 2019 (COVID-19).&#xD;
&#xD;
      The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of&#xD;
      care in patients hospitalized with COVID-19 pneumonia who are not requiring mechanical&#xD;
      ventilation or extracorporeal oxygenation (ECMO).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Leronlimab (PRO 140) is a humanized IgG4,k monoclonal antibody (mAb) that recognizes the C-C&#xD;
      chemokine receptor type 5 (CCR5). CCR5 is expressed predominantly on T cells but also found&#xD;
      on macrophages, dendritic cells, and eosinophils to mediate chemotaxis in response to its&#xD;
      cognate ligands that include CCL5 (RANTES), CCL3 (MIP-1α), and CCL4 (MIP-1β). These ligands&#xD;
      are integral in the recruitment of these immune cells to inflammatory sites. The&#xD;
      immunopathogenesis of COVID-19 likely involves the excessive influx of immune cells into the&#xD;
      lung. Disruption of the CCL5-CCR5 axis via leronlimab-mediated CCR5 blockade might prevent&#xD;
      pulmonary trafficking of pro-inflammatory leukocytes and dampen pathogenic immune activation&#xD;
      in COVID-19.&#xD;
&#xD;
      The purpose of the study is to assess the safety and efficacy of leronlimab plus standard of&#xD;
      care in patients hospitalized with COVID-19 pneumonia who are not requiring mechanical&#xD;
      ventilation or extracorporeal oxygenation (ECMO).&#xD;
&#xD;
      This is a Phase 3, 2-arm, randomized, double blind, placebo controlled, multicenter study to&#xD;
      evaluate the safety and efficacy of leronlimab (PRO 140) as an add on therapy to the&#xD;
      institutional standard of care (SoC) for the management of moderately ill patients with&#xD;
      COVID-19 pneumonia.&#xD;
&#xD;
      Patients will be randomized in a 1:1 ratio to receive up to four doses of leronlimab (PRO&#xD;
      140) or placebo. Leronlimab (700 mg followed by 350 mg weekly) or placebo will be&#xD;
      administered subcutaneously over a 4-week treatment period. No treatments will be&#xD;
      administered post-discharge.&#xD;
&#xD;
      The participant will be evaluated on each study day while hospitalized up until and including&#xD;
      Day 28. The daily visits will capture clinical status - ordinal scale and the occurrence of&#xD;
      adverse events. A complete follow-up assessment will be performed at Days 7, 14, 21, 28, 42&#xD;
      and 60 for those who are hospitalized at these specific timepoints. Follow-up visits can be&#xD;
      conducted as telephone or video contact visits, if subject is discharged from the hospital&#xD;
      prior to the complete follow-up visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 9, 2021</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of death or respiratory failure until day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Rates of participants who attain categories 6, 7, or 8 on the eight-category ordinal scale within 28 days&#xD;
Not hospitalized, no limitations on activities&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, on non-invasive ventilation or high flow oxygen devices&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to clinical recovery</measure>
    <time_frame>28 days</time_frame>
    <description>Categories 1, 2 and 3 on a 8-point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death or intubation until day 28</measure>
    <time_frame>28 days</time_frame>
    <description>Categories 7 or 8 on the eight-point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients clinically recovered</measure>
    <time_frame>Days 14, 28, 42, and 60</time_frame>
    <description>Categories 1, 2 and 3 on a 8-point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Days 14, 28, 42, and 60</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients discharged alive</measure>
    <time_frame>Days 14, 28, 42, and 60</time_frame>
    <description>Categories 1 and 2 on a 8-point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status</measure>
    <time_frame>Days 14, 28, 42, and 60</time_frame>
    <description>On a 8 point ordinal scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>28 days</time_frame>
    <description>days</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">612</enrollment>
  <condition>COVID-19 Pneumonia</condition>
  <arm_group>
    <arm_group_label>Leronlimab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Leronlimab subcutaneously once a week (up to 4 doses) until hospital discharge. The first dose will be of 700 mg, followed by weekly doses of 350 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneously once a week (up to 4 doses) until hospital discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leronlimab</intervention_name>
    <description>Leronlimab 700 mg (first dose) followed by weekly 350 mg</description>
    <arm_group_label>Leronlimab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or females aged ≥ 18 years&#xD;
&#xD;
          2. Moderately ill patients with COVID-19 (defined as Ordinal Scale of 5 or 6):&#xD;
             Hospitalized, requiring supplemental oxygen or hospitalized, on non-invasive&#xD;
             ventilation or high flow oxygen devices&#xD;
&#xD;
          3. Evidence of pneumonia (pulmonary infiltrates) at chest radiography or computed&#xD;
             tomography compatible with COVID-19.&#xD;
&#xD;
          4. Hospitalization for less than 72 hours, receiving standard of care treatment for&#xD;
             COVID-19.&#xD;
&#xD;
          5. Laboratory-confirmed novel coronavirus (SARS-CoV-2) infection as determined by&#xD;
             polymerase chain reaction (PCR).&#xD;
&#xD;
          6. Subject (or legally authorized representative) provides written or oral informed&#xD;
             consent prior to initiation of any study procedures.&#xD;
&#xD;
          7. Women of childbearing potential and their partner must agree to use at least one&#xD;
             highly effective method of contraception (e.g., hormonal contraceptives [implants,&#xD;
             injectables, combination oral contraceptives, transdermal patches, or contraceptive&#xD;
             rings], intrauterine devices, bilateral tubal occlusion, or sexual abstinence) for the&#xD;
             duration of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subjects on invasive mechanical ventilation or extracorporeal membrane oxygenation&#xD;
             (ECMO).&#xD;
&#xD;
          2. Subjects who have a history of allergic reactions attributed to compounds of similar&#xD;
             chemical or biologic composition to leronlimab (PRO 140) are not eligible.&#xD;
&#xD;
          3. Inability to provide informed consent (from subject or legally authorized&#xD;
             representative) or to comply with test requirements.&#xD;
&#xD;
          4. Other medical or psychiatric condition including recent (within the past year) or&#xD;
             active suicidal ideation/behavior or laboratory abnormality that may increase the risk&#xD;
             associated with study participation or, in the investigator's judgment, make the&#xD;
             participant inappropriate for the study.&#xD;
&#xD;
          5. Pregnancy or breast feeding.&#xD;
&#xD;
          6. Subject participating in another study with for an investigational treatment.&#xD;
&#xD;
          7. Suspected or known active systemic bacterial, fungal, or viral infections (with the&#xD;
             exception of COVID-19), that may increase the risk for the study participant based on&#xD;
             investigator judgement.&#xD;
&#xD;
          8. Participants who are immunocompromised, with known immunodeficiencies, or taking&#xD;
             potent immunosuppressive agents (e.g., azathioprine, cyclosporine).&#xD;
&#xD;
          9. Patients with estimated discharge or transfer for other hospital in the first 72 hours&#xD;
             of study inclusion.&#xD;
&#xD;
         10. Patients with low probability of survival in the first 48 hours of study inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Otavio Berwanger, MD, PhD</last_name>
    <phone>+551121515915</phone>
    <phone_ext>53945</phone_ext>
    <email>otavio.berwanger@einstein.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Patricia Guimaraes, MD, PhD</last_name>
    <phone>+551121515915</phone>
    <phone_ext>53945</phone_ext>
    <email>patricia.oguimaraes@einstein.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro de Estudos Clínicos do Hospital Cárdio Pulmonar</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marcel Albuquerque, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Ensino e Pesquisa do Hospital da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianna Dracoulakis, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia da Bahia - Hospital Santa Izabel</name>
      <address>
        <city>Salvador</city>
        <state>BA</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilson Feitosa-Filho, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital do Coração do Brasil</name>
      <address>
        <city>Brasília</city>
        <state>DF</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Fonseca, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital São Lucas Copacabana</name>
      <address>
        <city>Rio De Janeiro</city>
        <state>RJ</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Paolino, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Atena de Pesquisa Clínica</name>
      <address>
        <city>Natal</city>
        <state>RN</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Paiva, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital São Vicente de Paulo</name>
      <address>
        <city>Passo Fundo</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Tognon, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Mãe de Deus</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cristiano Jaeger, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Pesquisa Clínica do Coração</name>
      <address>
        <city>Aracaju</city>
        <state>SE</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabio Serra, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Irmandade do Sr. Bom Jesus dos Passos da Santa Casa de Misericórdia de Bragança Paulista</name>
      <address>
        <city>Bragança Paulista</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Murillo Antunes, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto de Pesquisa Clínica de Campinas</name>
      <address>
        <city>Campinas</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>José Saraiva, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundação Faculdade Regional de Medicina de São José do Rio Preto</name>
      <address>
        <city>São José Do Rio Preto</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lilia Maia, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Associação Beneficente Síria - Hospital do Coração (HCor)</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Cavalcanti, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital 9 de Julho</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eduardo Lima, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Alemão Oswaldo Cruz</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Victor Sato, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Beneficência Portuguesa</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Viviane Veiga, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital M'Boi Mirim</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niklas Campos, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Paula</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Otavio Gebara, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Votuporanga</name>
      <address>
        <city>Votuporanga</city>
        <state>São Paulo</state>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mauro Hernandes, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Israelita Albert Einstein</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Remo Furtado, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 24, 2021</study_first_submitted>
  <study_first_submitted_qc>May 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 25, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Pneumonia</keyword>
  <keyword>Leronlimab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leronlimab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

